Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3ε

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3185-3191

  Liou, Jun Yang ^a   Ghelani, Dipak ^a   Yeh, Sam ^a   Wu, Kenneth K ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN 14 3 3; PROTEIN BAD; SULINDAC SULFIDE; SULINDAC SULFONE; 4 (5 (4 CHLOROPHENYL) 3 (TRIFLUOROMETHYL) 1H PYRAZOL 1 YL)BENZENESULFONAMIDE; 4-(5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL)BENZENESULFONAMIDE; BAD PROTEIN, HUMAN; DRUG DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULINDAC; UNCLASSIFIED DRUG; YWHAE PROTEIN, HUMAN;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL PROTECTION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE OVEREXPRESSION; GENE REPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; CELL STRAIN HT29; COLORECTAL TUMOR; DRUG ANTAGONISM; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY;

14-3-3 PROTEINS; ADENOVIRIDAE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; HT29 CELLS; HUMANS; INDOMETHACIN; MITOCHONDRIA; PPAR DELTA; PROMOTER REGIONS (GENETICS); PYRAZOLES; SULFONAMIDES; SULINDAC;

EID: 34248174248     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3431     Document Type: Article

References (45)

1. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
2. Thun MJ. Aspirin and gastrointestinal cancer. Adv Exp Med Biol 1997;400A:395-402.
3. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-20.
4. Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996;56:710-4.
5. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998;114:873-7.
6. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-8.
7. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002;122:641-5.
8. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
9. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
10. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
11. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-15.
12. Piazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110-6.
13. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491-503.
14. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-45.
15. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc Natl Acad Sci U S A 2000;97:13275-80.
16. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat Med 2004;10:245-7.
17. Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A 2001;98:2598-603.
18. Tan NS, Michalik L, Noy N, et al. Critical roles of PPAR β/δ in keratinocyte response to inflammation. Genes Dev 2001;15:3263-77.
19. Hao CM, Redha R, Morrow J, Breyer MD. Peroxisome proliferator-activated receptor 8 activation promotes cell survival following hypertonic stress. J Biol Chem 2002;277:21341-5.
20. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B. Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 2002;10:721-33.
21. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-6 mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2006;26:1481-7.
22. Crawford LJ, Walker B, Ovaa H, et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006;66:6379-86.
23. Kim SH, Yoo CI, Kim HT, Park JY, Kwon CH, Kim YK. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol Appl Pharmacol 2006;215:198-207.
24. Shyue SK, Tsai MJ, Liou JY, Willerson JT, Wu KK Selective augmentation of prostacyclin production by combined prostacyclin synthase and cyclooxygenase-1 gene transfer. Circulation 2001;103:2090-5.
25. Liou JY, Shyue SK, Tsai MJ, Chung CL, Chu KY, Wu KK. Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells. J Biol Chem 2000;275:15314-20.
26. Liou JY, Aleksic N, Chen SF, Han TJ, Shyue SK, Wu KK. Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res 2005;306:75-84.
27. Blankson H, Grotterod EM, Seglen PO. Prevention of toxin-induced cytoskeletal disruption and apoptotic liver cell death by the grapefruit flavonoid, naringin. Cell Death Differ 2000;7:739-46.
28. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
29. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619.
30. Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000;40:617-47.
31. Tzivion G, Avruch J. 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 2002;277:3061-4.
32. Zhou XM, Liu Y, Payne G, Lutz RJ, Chittenden T. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 2000;275:25046-51.
33. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996;61:514-23.
34. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res 2000;60:3338-42.
35. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grosch S. Targeting the β-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005;19:1353-5.
36. Chiu CH, McEntee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997;57:4267-73.
37. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-47.
38. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
39. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679-83.
40. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 2005;310:1504-9.
41. Lu D, Cottam HB, Corr M, Carson DA. Repression of β-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A 2005;102:18567-71.
42. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000;290:989-92.
43. Richter M, Weiss M, Weinberger I, Furstenberger G, Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001;22:17-25.
44. Kohli M, Yu J, Seaman C, et al. SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc Natl Acad Sci U S A 2004;101:16897-902.
45. Rice PL, Washington M, Schleman S, Beard KS, Driggers LJ, Ahnen DJ. Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res 2003;63:616-20.